Key Drivers
- Liquidity strength
- Heavy cash burn
- Weak profitability
AIAI Summary
ALMS should be viewed less as a cash-starved speculative biotech and more as a late-stage, catalyst-driven psoriasis story with a strong balance sheet, but the investment still hinges almost entirely on envudeucitinib converting its Phase 3 momentum into NDA/regulatory progress before weak price action and single-asset dependence erode sentiment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity strength
- •Heavy cash burn
- •Weak profitability
ALMS combines a very strong balance sheet and liquidity with persistent losses, negative free cash flow, and weak operating efficiency, making the stock financially resilient but fundamentally unproven.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Lower highs
- •Rebound failure
ALMS has shifted into a weak short-term downtrend over the last month, breaking $22.89 support after a failed rebound and leaving only a limited bounce case unless it reclaims the $23.50-$24.86 area.
Rebounded from $22.89 to $26.13, then quickly reversed to a new low at $22.87
Sentiment & News
Key News Insights:
- •Investor support
- •Phase 3 data
- •Psoriasis momentum
ALMS is drawing investor support while advancing promising Phase 3 psoriasis data for its TYK2-focused autoimmune pipeline.
This is a positive catalyst for ALMS, reinforcing confidence in its late-stage pipeline and clinical execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings